ERBB2 and breast carcinoma: Furthermore, we observed an increase in sTK1 even after short exposure to neoadjuvant treatment, similar to our previous findings on HER2-negative breast cancer treated with chemotherapy [11], and in contrast with available data on neoadjuvant endocrine-treated disease [10].